Navigation Links
/C O R R E C T I O N -- Rosetta Genomics Ltd/
Date:5/21/2008

e first quarter of 2008 was $3.7 million (including a non-cash expense of $191,000 related to stock based compensation), compared with an operating loss of $2.2 million (including a non-cash expense of $205,000 related to stock based compensation) for the corresponding quarter of 2007. Net loss for the first quarter of 2008 was $3.9 million, or $0.33 per ordinary share, compared with a net loss of $2 million, or $0.23 per ordinary share, for the corresponding quarter of 2007.

Research and development expenses of $2.4 million for the first quarter of 2008, compared to $1.2 million for the first quarter of 2007, remain the Company's largest expense and accounted for 64% of its operating losses.

As of March 31, 2008 we had $18.6 million in cash, cash equivalents, short and long term bank deposits and marketable securities. Our outlook of total cash usage for operating activities for the next nine month of 2008 is approximately $10 million.

As previously announced, the Company continues to receive interest payments from its auction rate securities, which all but two are rated AAA. However, due to the continuing uncertainty in the credit market, the company recorded an impairment of $300,000 during the first quarter.

Recent Highlights

Rosetta Genomics reports the following scientific and corporate highlights:

Diagnostic Programs

- Squamous vs. Non Squamous non-small cell lung cancer (NSCLC) - Columbia University Medical Center's Molecular Pathology Laboratory has submitted this test, designed to differentiate squamous from non squamous non-small cell lung cancer (NSCLC) using a single microRNA, for regulatory approval to the New York State Department of Health. The approval process is estimated to take 2-6 months.

The ability of physicians to accurately differentiate squamous from non-squamous NSCLC is an important treatment guide. Bevacizumab, an angiogenesis inhibitor and an important new modality of therapy for n
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015 Sanofi, un leader ... résultats pour le premier semestre 2015. Le Directeur ... Visionner l,interview vidéo et lire la ... Au sommaire de l,interview :  ... croissance - Diabète - ...
(Date:7/29/2015)... 2015  HealthSouth Corporation (NYSE: HLS ... post-acute healthcare services, offering both facility-based and home-based ... for the second quarter ended June 30, 2015. ... strong volume growth in both segments and an ... Grinney, President and Chief Executive Officer of HealthSouth. ...
(Date:7/29/2015)...  AmnioChor Inc., an early stage biotech startup based ... announce that the Musculoskeletal Transplant Foundation of ... their seed round of development of the proprietary AmnioCept™ ... AmnioChor,s technology allows cryopreservation of the amniotic ... living within those tissues. Amnion is a well-established source ...
(Date:7/29/2015)... 29, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... company, is pleased to announce that the final design ... been locked.  Prototypes for industrial and regulatory testing ... application for CE mark clearance to market the ... 2016. (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  ...
Breaking Biology Technology:HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31HealthSouth Reports Results for Second Quarter 2015 32HealthSouth Reports Results for Second Quarter 2015 33HealthSouth Reports Results for Second Quarter 2015 34HealthSouth Reports Results for Second Quarter 2015 35HealthSouth Reports Results for Second Quarter 2015 36
... its Fiscal Year 2009" issued on 15 Mar,2010 13:20 GMT , by Health Robotics over PR Newswire, we are ... Complete, corrected release follows: , ... , ... ...
... radionuclide - , ... ... - Interaction of ... , ...
... and OXFORD, England , March ... PharmaVentures Limited ("PharmaVentures"),today announced the signing of a ... biotech, pharmaceutical and med tech sectors.,The companies will ... consolidation opportunities which bring together both strategic,expertise and ...
Cached Biology Technology:/C O R R E C T I O N -- Health Robotics/ 2/C O R R E C T I O N -- Health Robotics/ 3/C O R R E C T I O N -- Health Robotics/ 4/C O R R E C T I O N -- Health Robotics/ 5/C O R R E C T I O N -- Health Robotics/ 6/C O R R E C T I O N -- Health Robotics/ 7/C O R R E C T I O N -- Health Robotics/ 8/C O R R E C T I O N -- Health Robotics/ 9/C O R R E C T I O N -- Health Robotics/ 10/C O R R E C T I O N -- Health Robotics/ 11/C O R R E C T I O N -- Health Robotics/ 12/C O R R E C T I O N -- Health Robotics/ 13/C O R R E C T I O N -- Health Robotics/ 14/C O R R E C T I O N -- Health Robotics/ 15/C O R R E C T I O N -- Health Robotics/ 16/C O R R E C T I O N -- Health Robotics/ 17YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 2YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 3YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 4YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 5YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 6YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations 7Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU) 2Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU) 3Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU) 4
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/km7m5t/natural_language ... "Natural Language Processing Market by Type (Rule-Based, Statistical, ... Image Recognition) - Worldwide Forecast to 2020" ... vendors occupying the market are 3M, Apple, Dolbey ... Solutions, SAS Institute Inc., Verint Systems among various ...
(Date:6/30/2015)... -- To bolster its efforts and commitment to fighting cyber ... addition of two new team members. ... David Raviv will act as head of strategic alliances. ... providing the most secure solutions for the enterprise market. ... Technologies, a provider of security and management products, which was ...
(Date:6/26/2015)... 26, 2015 ATL Technology, LLC, a top provider ... in single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Jose, Costa Rica ). This acquisition will ... with ATL Technology,s existing facility in Costa ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2
... or two from turtles, and scientists who have just sequenced ... benefit from the shelled creatures, remarkable longevity and ability to ... natural mechanisms turtles use to protect their heart and brain ... attack and stroke, the researchers said. UCLA ...
... in Spanish . Researchers at the ... centre have discovered a new therapy for the fragile X ... cerebral endocannabinoid system in order to ameliorate the symptoms of ... to be achieved, as it involves a disease of genetic ...
... , April 10, 2013  Venetian Ballroom E – ... solutions, announced today the introduction of the new HBOX ® , its ... at the Stanley Security Solutions, Venetian Ballroom E during ... .  Capable of authenticating 50 people per minute, ...
Cached Biology News:Scientists decode genome of painted turtle, revealing clues to extraordinary adaptations 2Scientists decode genome of painted turtle, revealing clues to extraordinary adaptations 3New therapy for fragile X chromosome syndrome discovered 2EyeLock Debuts Its New HBOX Iris Authentication System at ISC West 2EyeLock Debuts Its New HBOX Iris Authentication System at ISC West 3
... Thermo Savant SpeedVac Concentrators set the standard ... SC110A SpeedVac uses a combination of centrifugal force, ... a single run., SC110A comes equipped with:, , ... chemical compatibility , ...
... SpeedVac to have active, real-time sample temperature ... is the worlds first, fully modular SpeedVac ... stacked together to form an integrated unit ... is also the first SpeedVac to have ...
... Jouan RC Standard Bio for vacuum ... of molecular biology and biochemistry for rapid ... RC systems can be expanded with pumps, ... selection of rotors (eliminating sample loss by ...
... is a dedicated concentrator for efficient drying ... DNA/RNA. The integrated system combines the SpeedVac™ ... compact design, automatic pump and rotor control, ... one for heater time), makes the DNA120 ...
Biology Products: